Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

29.22 -0.05 (-0.17%)
Official Closing Price Updated: 7:00 PM EDT, Oct 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 24,257,402
Open 29.30
Bid (Size) 29.20 (5)
Ask (Size) 29.24 (40)
Prev. Close 29.27
Today's Range 29.08 - 29.36
52wk Range 25.20 - 31.54
Shares Outstanding 5,606,688,356
Dividend Yield 5.61%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Yes, bargains can still be found in the stock market. 
Via The Motley Fool
3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now
These stocks could deliver big over the long term. 
Via The Motley Fool

Performance

YTD
-1.72%
-1.72%
1 Month
-1.78%
-1.78%
3 Month
-2.50%
-2.50%
6 Month
+12.38%
+12.38%
1 Year
-6.32%
-6.32%

More News

Read More
Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
Guggenheim's Longstanding Pfizer Ties Tested Amid Starboard Battle
Via Benzinga
Why I'm Considering Leaning Heavily Into Pfizer
Via The Motley Fool
Pfizer’s Seasonal Strength And Starboard’s Activist Move
Via Talk Markets
(PFE) - Analyzing Pfizer's Short Interest
Via Benzinga
GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Tim Buckley Elected to Pfizer’s Board of Directors
From Pfizer Inc.
Via Business Wire
Pfizer Is Clashing With Its New Activist Investor. Will It Harm The Stock?
Via The Motley Fool
2 Ultra-High-Yield Dividend Stocks With Total Return Potential of Up to 92% in 12 Months, According to Select Wall Street Analysts
Via The Motley Fool
The Bull's Biggest Hits And Misses
Via Talk Markets
Topics Stocks
Exposures US Equities
Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce
Via Talk Markets
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
Via Investor's Business Daily
Which Pharma Stock Is the Better Bargain Buy: Pfizer or Eli Lilly?
Via The Motley Fool
FDA Approves Pfizer's Second Hemophilia Drug With Six Months
Via Benzinga
Exposures Product Safety
Prediction: These 2 High-Yield Dividend Stocks Will Outperform the S&P 500 Index in the Coming Decade
Via The Motley Fool
Topics Stocks
Exposures US Equities
2 Unstoppable Growth Stocks to Buy Right Now for Less than $200
Via The Motley Fool
2 Incredibly Cheap Big Pharma Stocks to Buy Now
Via The Motley Fool
3 Reliable Dividend Stocks With Yields Above 5% That You Can Buy With Less Than $100 Right Now
Via The Motley Fool
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
Via Benzinga
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
From Pfizer Inc.
Via Business Wire
Stock Market Rallies As S&P 500, Dow Hit Highs; Tesla Robotaxi Isn't Hailed, Delta, JPMorgan In Focus: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
An Activist Investor Just Bought $1 Billion Worth of Pfizer. Here's What It Means for the Stock
Via The Motley Fool
Why Pfizer Stock Tumbled by Nearly 3% on Thursday
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.